_edited.jpg){kind=logo}
Overview
The start-up develops synthetic bacteriophage products as a sustainable alternative to antibiotics. Their a patent pending technology to design tailor-made synthetic bacteriophages, delivers a bacteriophage kill rate of up to 100%, in contrast to the 60% of natural ones. This technology is totally safe, without affecting helpful bacteria, animal or human cells.
Pilot Objectives
✔ Technology Validation with lab tests on phages to contrast partner’s salmonella bacterial strains.
✔ Assessment and collection of the documentation for the application submission to the Ministry of Health in order to run on-field tests.
コメント